Inflammasomes are important mediators of prostatic inflammation associated with BPH
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1476-9255
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Inflammasomes are important mediators of prostatic inflammation associated with BPH ; volume:12 ; number:1 ; day:17 ; month:5 ; year:2015 ; pages:1-8 ; date:12.2015
Journal of Inflammation ; 12, Heft 1 (17.5.2015), 1-8, 12.2015
- Creator
-
Kashyap, Mahendra
Pore, Subrata
Wang, Zhou
Gingrich, Jeffrey
Yoshimura, Naoki
Tyagi, Pradeep
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12950-015-0082-3
- URN
-
urn:nbn:de:101:1-2021082823032865493465
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:33 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kashyap, Mahendra
- Pore, Subrata
- Wang, Zhou
- Gingrich, Jeffrey
- Yoshimura, Naoki
- Tyagi, Pradeep
- SpringerLink (Online service)
Other Objects (12)
What is a disease? What is the disease clinical benign prostatic hyperplasia (BPH)?
Lipid mediators in eye inflammation
Plasma metabolites as mediators in the relationship between inflammation-related proteins and benign prostatic hyperplasia: insights from mendelian randomization
Mediators of liver inflammation and carcinogenesis
Heritability and genome-wide association study of benign prostatic hyperplasia (BPH) in the eMERGE network
Resveratrol induces apoptosis of benign prostatic hyperplasia epithelial cell line (BPH-1) through p38 MAPK-FOXO3a pathway
Medikamentöse BPH-Behandlung
B-P-H
Cytotoxic mediators of inflammation and host defence
Blickpunkt Benigne Prostatahyperplasie (BPH)
Therapie der BPH-Erkrankung
Longitudinal association between the dynamic nature of depression with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH)
What is a disease? What is the disease clinical benign prostatic hyperplasia (BPH)?
Lipid mediators in eye inflammation
Plasma metabolites as mediators in the relationship between inflammation-related proteins and benign prostatic hyperplasia: insights from mendelian randomization
Mediators of liver inflammation and carcinogenesis
Heritability and genome-wide association study of benign prostatic hyperplasia (BPH) in the eMERGE network
Resveratrol induces apoptosis of benign prostatic hyperplasia epithelial cell line (BPH-1) through p38 MAPK-FOXO3a pathway
Medikamentöse BPH-Behandlung
B-P-H
Cytotoxic mediators of inflammation and host defence
Blickpunkt Benigne Prostatahyperplasie (BPH)
Therapie der BPH-Erkrankung
Longitudinal association between the dynamic nature of depression with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH)
What is a disease? What is the disease clinical benign prostatic hyperplasia (BPH)?
Lipid mediators in eye inflammation
Plasma metabolites as mediators in the relationship between inflammation-related proteins and benign prostatic hyperplasia: insights from mendelian randomization
Mediators of liver inflammation and carcinogenesis
Heritability and genome-wide association study of benign prostatic hyperplasia (BPH) in the eMERGE network
Resveratrol induces apoptosis of benign prostatic hyperplasia epithelial cell line (BPH-1) through p38 MAPK-FOXO3a pathway
Medikamentöse BPH-Behandlung
B-P-H
Cytotoxic mediators of inflammation and host defence
Blickpunkt Benigne Prostatahyperplasie (BPH)
Therapie der BPH-Erkrankung